ArticleFrontiers in pediatrics2020
Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic.
Article in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review.BMC infectious diseases · 2024Pooled it
- Pediatric health: mechanistic insights into inflammatory diseases and emerging therapeutic pathway-targeted approaches.Translational pediatrics · 2026Review
- Research Progress on Coronary Artery Injury and Myocardial Ischemia in Multisystem Inflammatory Syndrome in Children.Current issues in molecular biology · 2026Review
- Cytokine storm.Nature reviews. Disease primers · 2026Review
- Successfully Overcoming Allergy to Anakinra Through Intravenous Desensitization in a Child "Case Report".Case reports in immunology · 2025Article
- Innate and adaptive immunity in acute myocarditis.International journal of cardiology · 2024Review
- Treatment of multisystem inflammatory syndrome in children.World journal of pediatrics : WJP · 2024Review
- Cytokines in Cytokine Storm Syndrome.Advances in experimental medicine and biology · 2024Review
- Multisystem Inflammatory Syndrome in Children: Two Years' Worth of Learning.Clinical pediatrics · 2024Article
- Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study.Pediatric rheumatology online journal · 2023Article
- Variation in Early Anakinra Use and Short-Term Outcomes in Multisystem Inflammatory Syndrome in Children.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?Children (Basel, Switzerland) · 2023Article
- Incidence and Prevalence of Multisystem Inflammatory Syndrome in Children (MIS-C) in Southern Italy.Children (Basel, Switzerland) · 2023Article
- Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study.Frontiers in pediatrics · 2023Article
- Hemolytic anemia following intravenous immunoglobulins in children with PIMS-TS: Two case reports.Frontiers in pediatrics · 2023Article
- Update on the treatment of multisystem inflammatory syndrome in children associated with COVID-19.Future virology · 2022Review
- Current evidence on the use of anakinra in COVID-19.International immunopharmacology · 2022Review
- COVID-19 and the cardiovascular system: an update.The American journal of the medical sciences · 2022Review
- IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2.The Lancet. Rheumatology · 2022Article
- Distinguishing immune activation and inflammatory signatures of multisystem inflammatory syndrome in children (MIS-C) versus hemophagocytic lymphohistiocytosis (HLH).The Journal of allergy and clinical immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During COVID-19 outbreak, a large number of children with severe inflammatory disease has been reported. This condition, named Pediatric Multi-inflammatory Syndrome temporally associated with COVID-19 (PIMS-TS) or Multisystem Inflammatory Syndrome associated with Coronavirus Disease 2019 (MIS-C), shares some clinical features with Kawasaki disease and is frequently complicated by myocarditis or shock. It has been suggested that MIS-C belongs to the group of cytokine storm syndromes triggered by SARS-CoV-2 infection. So far, intravenous immunoglobulin (IVIG) and systemic glucocorticoids are the most common therapeutic approaches reported in this group of patients. However, the use of anakinra in patients with severe forms of COVID-19 is showing promising results. Here we reported two patients with multisystem inflammatory syndrome complicated with shock. Both the patients presented a poor response to IVIG and systemic glucocorticoids and received anakinra. Treatment with IL-1 receptor antagonist showed a rapid improvement of clinical conditions and biochemical analysis in both patients and demonstrated a good safety profile. Thus, we look forward for future controlled clinical trials with the aim to demonstrate the effectiveness of anakinra in patients with MIS-C and established precise criteria for its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.